ISTH 2021 Congress
COVID and Coagulation
Theme Navigation
- ISTH 2021 Congress
- COVID and Coagulation
-
Abstract Number: PB0186
A Weight-based Approach to Thromboprophylaxis Dosing for Medical Inpatients with COVID-19
-
Abstract Number: PB0190
ACE2, ACE and Thromboinflammation in COVID-19
-
Abstract Number: PB0299
Acute Liver Necrosis in a Sars-Cov-2 Positive Patient with Triple Positive Antiphospholipid Syndrome
-
Abstract Number: PB0168
Adjusting D-dimer to Lung Disease Extent to Exclude Pulmonary Embolism in COVID-19 Patients (Co-LEAD)
-
Abstract Number: PB0270
After the Storm; 6-month Follow up Outcomes and Management of COVID-19 Related Venous Thromboembolism
-
Abstract Number: PO129
Alterations of the Coagulation Profile in Peruvians Admitted for Pneumonia due to SARS-COV2: Cross-sectional Study
-
Abstract Number: OC 15.2
Altered Platelet Proteome and Platelet-leukocyte Interactions in Patients with COVID-19
-
Abstract Number: PB0159
Altered Protein S Activity Contributes Significantly to COVID-19 Pro-thrombotic State
-
Abstract Number: PB0300
Analysing Risk Factors for Thrombosis in Covid-19 and Cancer Patients
-
Abstract Number: PB0204
Anemia and Enhancement of Coagulation Are Associated during Severe COVID-19 Infection
-
Abstract Number: PB0280
Anti-coagulant Drugs among Moderate, Severe and Critically Ill COVID 19 Patients in the Second Referral Hospital in Surabaya
-
Abstract Number: PB0184
Anti-factor Xa Activity after Intermediate Dose Nadroparin for Thrombosis Prophylaxis in Critically Ill COVID-19 Patients with and without Acute Kidney Injury
-
Abstract Number: OC 70.2
Anti-thrombotics and Anti-hypertensives with Direct Action against SARS-CoV-2
-
Abstract Number: PB0262
Anticoagulant Response to Tailored Low Molecular Weight Heparin Regimens in Patients with COVID-19 Infection
-
Abstract Number: PB0202
Anticoagulation Strategies and Risk Of Bleeding Events in Critically ill COVID-19 Patients
-
Abstract Number: PB0230
Anticoagulation with Tinzaparin in COVID-19 Patients in ICU: Are Low Anti-Xa Levels Associated with the Development of Thrombo-embolic Events?
-
Abstract Number: PB0247
Apparent Different of Lupus Anticoagulant Disappearance in Novel Coronavirus 2019 Patients as a Distinct Clinical Feature
-
Abstract Number: PB0173
Are Mild or Moderate COVID-19 Patients at Higher Risk of VTE? A Comparison of Two Prospective European Cohorts in Emergency Departments
- 1
- 2
- 3
- …
- 11
- Next Page »